Innate Pharma reports first half 2021 financial results and business update

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) —

  • First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2
  • New pre-clinical data…

Click here to view the original article.